CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC

• Main Authors: Wangta Liu (Author), Yu-Lun Lo (Author), Chin Hsu (Author), Yi-Ting Wu (Author), Zi-Xian Liao (Author), Wen-Jeng Wu (Author), Yi-Jou Chen (Author), Chieh Kao (Author), Chien-Chih Chiu (Author), Li-Fang Wang (Author)
• Format: Book
• Published: Elsevier, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Paclitaxel (PTX) is a widely used chemotherapy drug; however, frequent use causes multidrug resistance (MDR), which limits the utility of PTX against advanced non-small-cell lung cancer (NSCLC). PTX-resistant subline (NCI-H23-TXR) was established in vitro by exposing NCI-H23 cells to gradually incre...